The pathogenic role of persistent milk signaling in mTORC1-and milk-microRNA-driven type 2 diabetes mellitus

Current Diabetes Reviews

Volumn 11, Issue 1, 2015, Pages 46-62

  Melnik, Bodo C ^a  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

Branched chain amino acid dysmetabolism; Diabetogenic milk derived microRNAs; Endoplasmic reticulum stress; mTORC1; Type 2 diabetes mellitus; cell apoptosis

Indexed keywords

2 OXOACID DEHYDROGENASE; ANTIDIABETIC AGENT; BRANCHED CHAIN AMINO ACID; GLUTAMINE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; METFORMIN; MICRORNA; MICRORNA 21; MICRORNA 29B; PALMITIC ACID; PROTEIN MCL 1; SOMATOMEDIN C; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; DIABETOGENESIS; DIET; ENDOPLASMIC RETICULUM STRESS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; LIFESTYLE; MILK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; ADVERSE EFFECTS; ANIMAL; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM STRESS; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICRORNAS; MILK; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84926285465     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811666150114100653     Document Type: Article

References (274)

1. [1] Forouhi NG, Wareham NJ. The EPIC-InterAct Study: A study of the interplay between genetic and lifestyle behavioral factors on the risk of type 2 diabetes in European populations. Curr Nutr Rep 2014; 3: 355-63.
2. Reference: Available from: http://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-inthe-united-states.pdf&ie=UTF-8&oe=UTF-8&gfe_rd=cr&ei=mHliVIynHNKq8weeiIHADQ.
3. [3] Akash MS, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 2012; 101: 1647-58.
4. [4] Akash MS, Rehman K, Chen S. An overview of valuable scientific models for diabetes mellitus. Curr Diabetes Rev 2013; 9: 286-93.
5. [5] Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2013; 114: 525-31.
6. [6] Kitamura T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol 2013; 9: 615-23.
7. [7] CDC’s Division of Diabetes Translation. Long-term trends in diagnosed diabetes. October 2011; http://www.cdc.gov/diabetes/statistics.
8. [8] Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Rev Mol Cell Biol 2011; 12: 21-35.
9. [9] Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-45.
10. [10] Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013; 23: 53-62.
11. [11] Oddo S. The role of mTOR signaling in Alzheimer disease. Front Biosci 2012; S4: 941-52.
12. [12] Tang Z, Bereczki E, Zhang H, et al. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem 2013; 288: 15556-70.
13. [13] Mendelsohn AR, Larrick JW. Dissecting mammalian target of rapamycin to promote longevity. Rejuvenation Res 2012; 15: 334-7.
14. [14] Xu S, Cai Y, Wei Y. mTOR signaling from cellular senescence to organismal aging. Aging Dis 2014; 5: 263-73.
15. [15] Melnik BC, John SM, Schmitz G. Milk is not just food but most likely a genetic transfection system activating mTORC1 signaling for postnatal growth. Nutr J 2013; 12: 103.
16. [16] McDaniel ML, Marshall CA, Pappan KL, Kwon G. Metabolic and autocrineregulation of the mammalian target of rapamycin by pancreatic β-cells. Diabetes 2002; 51: 2877-85.
17. [17] Leibowitz G, Cerasi E, Ketzinel-Gilad M. The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. Diabetes Obes Metab 2008; 10: 157-69.
18. [18] Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Nutr Rev 2010; 68: 270-9.
19. [19] Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. J Endocrinol 2013; 216: 21-9.
20. [20] Foster KG, Fingar DC: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010; 285: 14071-7.
21. [21] Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005; 69: 79-100.
22. [22] Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 2009; 296: E592-602.
23. [23] Sengupta S, Peterson T, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-22.
24. Laplante M, Sabatini DM. mTOR signaling. Cold Spring Harb Perspect Biol 2012; 4:pii: a011593.
25. [25] Kim J, Guan KL. Amino acid signaling in TOR activation. Ann Rev Biochem 2011; 80: 1001-32.
26. [26] Kim S, Buel GR, Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells 2013; 35: 463-73.
27. [27] Jewell JL, Guan KL. Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 2013; 38: 233-42.
28. [28] Efeyan A, Sabatini DM. Nutrients and growth factors in mTORC1 activation. Biochem Soc Trans 2013; 41: 902-5.
29. [29] Laplante M, Sabatini DM: Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 2013; 126: 1713-9.
30. [30] Wang X, Proud CG. Nutrient control of mTORC1, a cell-cycle regulator. Trends Cell Biol 2009; 19: 260-7.
31. [31] Chakrabarti P, English T, Shi J, Smas CM, Kandror KV. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes 2010; 59: 775-81.
32. [32] Ricoult SJ, Manning BD. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep 2013; 14: 242-51.
33. [33] Yamin HB, Barnea M, Genzer Y, Chapnik N, Froy O. Long-term commercial cow's milk consumption and its effects on metabolic parameters associated with obesity in young mice. Mol Nutr Food Res 2014; 58: 1061-8.
34. [34] Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans 2013; 41: 906-12.
35. [35] Yoon MS, Zhang C, Sun Y, Schoenherr CJ, Chen J. Mechanistic target of rapamycin controls homeostasis of adipogenesis. J Lipid Res 2013; 54: 2166-73.
36. [36] Xu J, Ji J, Yan XH. Cross-talk between AMPK and mTOR in regulating energy balance. Crit Rev Food Sci Nutr 2012; 52: 373-81.
37. [37] Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004; 101: 3329-35.
38. [38] Haissaguerre M, Saucisse N, Cota D. Influence of mTOR in energy and metabolic homeostasis. Mol Cell Endocrinol 2014; 397: 67-77.
39. [39] Dodd KM, Tee AR. Leucine and mTORC1: a complex relationship. Am J Physiol Endocrinol Metab 2012; 302: E1329-42.
40. [40] Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-34.
41. [41] Cohen A, Hall MN. An amino acid shuffle activates mTORC1. Cell 2009; 136: 399-400.
42. [42] Duran RV, Oppliger W, Robitaille AM, et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349-58.
43. [43] Yasuda M, Tanaka Y, Kume S, et al. Fatty acids are novel nutrient factors to regulate mTORC1 lysosomal localization and apoptosis in podocytes. Biochim Biophys Acta 2014; 1842: 1097-108.
44. [44] Millward DJ, Layman DK, Tomé D, Schaafsma G. Protein quality assessment: impact of expanding understanding of protein and amino acid needs for optimal health. Am J Clin Nutr 2008; 87: 1576S-81S.
45. [45] Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrère B. Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci U S A 1997; 94: 14930-5.
46. [46] He T, Giuseppin ML. Slow and fast dietary proteins differentially modulate postprandial metabolism. Int J Food Sci Nutr 2014; 65: 386-90.
47. [47] Boutrou R, Gaudichon C, Dupont D, et al. Sequential releases of milk protein-derived bioactive peptides in the jejunum in healthy humans. Am J Clin Nutr 2013; 97: 1414-23.
48. [48] Mahé S, Roos N, Benamouzig R, et al. Gastrojejunal kinetics and the digestion of [15N] beta-lactoglobulin and casein in humans: the influence of the nature and quantity of the protein. Am J Clin Nutr 1996; 63: 546-52.
49. [49] Lenders CM, Liu S, Wilmore DW, et al. Evaluation of a novel food composition database that includes glutamine and other amino acids derived from gene sequencing data. Eur J Clin Nutr 2009; 63: 1433-9.
50. [50] Li M, Li C, Allen A, Stanley CA, Smith TJ. The structure and allosteric regulation of mammalian glutamate dehydrogenase. Arch Biochem Biophys 2012; 519: 69-80.
51. [51] Lorin S, Tol MJ, Bauvy C, et al. Glutamate dehydrogenase contributes to leucine sensing in the regulation of autophagy. Autophagy 2013; 9: 850-60.
52. [52] Xu G, Kwon G, Cruz WS, Marshall CA, McDaniel ML. Metabolic regulation by leucine of translation initiation through the mTORsignaling pathway by pancreatic beta-cells. Diabetes 2001; 50: 353-60.
53. [53] Holt S, Brand Miller J, Petocz P. An insulin index of foods. The insulin demand generated by 1000-kK portions of common foods. Am J Clin Nutr 1997; 66: 1264-76.
54. [54] Hoyt G, Hickey MS, Cordain L. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Br J Nutr 2005; 93: 175-7.
55. [55] Hoppe C, Mølgaard C, Dalum C, Vaag A, Michaelsen KF. Differential effects of casein versus whey on fasting plasma levels of insulin, IGF-1 and IGF-1/ IGFBP-3: results from a randomized 7-day supplementation study in prepubertal boys. Eur J Clin Nutr 2009; 63: 1076-83.
56. [56] Thomas FB, Sinar D, Mazzaferri EL, et al. Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. Gastroenterology 1978; 74: 1261-5.
57. [57] Chen Q, Reimer RA. Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition 2009; 25: 340-9.
58. [58] Nilsson M, Stenberg M, Frid AH, Holst JJ, Björck IM. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr 2004; 80: 1246-53.
59. [59] Nilsson M, Holst JJ, Björck IM. Metabolic effects of amino acid mixtures and whey protein in helathy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr 2007; 85: 996-1004.
60. [60] Salehi A, Gunnerud U, Muhammed SJ, et al. The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β-cells. Nutr Metab (Lond) 2012; 9: 48.
61. [61] Lacroix IM, Li-Chan EC. Inhibition of dipetidyl peptidase (DPP)-IV and β-glucosidase actitvities by pepsin-treated whey proteins. J Agric Food Chem 2013; 61: 7500-6.
62. [62] Power O, Nongonierma AB, Jakeman P, FitzGerald RJ. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes. Proc Nutr Soc 2014; 73: 34-46.
63. [63] Hoppe C, Mølgaard C, Vaag A, Barkholt V, Michaelsen KF. High intakes of milk, but not meat, increases s-insulin and insulin resistance in 8-year-old boys. Eur J Clin Nutr 2005; 59: 393-8.
64. [64] Schusdziarra V, Schick A, de la Fuente A, et al. Effect of β-casomorphins and analogs on insulin release in dogs. Endocrinology 1983; 112: 855-9.
65. [65] Qin LQ, He K, Xu JY. Milk consumption and circulating insulinlike growth factor-I level: a systematic literature review. Int J Food Sci Nutr 2009; 60: 330-40.
66. [66] Norat T, Dossus L, Rinaldi S, et al. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr 2007; 61: 91-8.
67. [67] Rich-Edwards JW, Ganmaa D, Pollak MN, et al. Milk consumption and the prepubertal somatotropic axis. Nutr J 2007; 6: 28.
68. [68] Larnkjær A, Arnberg K, Michaelsen KF, Jensen SM, Mølgaard C. Effect of milk proteins on linear growth and IGF variables in overweight adolescents. Growth Horm IGF Res 2014; 24: 54-9.
69. [69] Melnik BC: Leucine signaling in the pathogenesis of type 2 diabetes and obesity. World J Diabetes 2012; 3: 38-53.
70. [70] Jensen RG, Ferris AM, Lammi-Keefe CJ. The composition of milk fat. J Dairy Sci 1991; 74: 3228-43.
71. [71] Bitman J, Wood DL. Changes in milk fat phospholipids during lactation. J Dairy Sci 1990; 73: 1208-16.
72. [72] Valadi H, Ekstöm K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNA and microRNAs is novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
73. [73] Liang H, Huang L, Cao J, Zen K, Chen X, Zhang CY. Regulation of mammalian gene expression by exogeneous microRNAs. Wiley Interdiscip Rev RNA 2012; 3: 733-42.
74. [74] Chen X, Liang H, Zhang J, Zen K, Thang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012; 22: 125-32.
75. [75] Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
76. [76] Ludwig AK, Giebel B. Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol 2012; 44: 11-5.
77. [77] Witwer KW, Hirschi KD. Transfer and functional consequences of dietary microRNAs in vertebrates: Concepts in search of corroboration. Bioessays 2014; 36: 394-406.
78. [78] Dickinson B, Zhang Y, Petrick JS, Heck G, Ivashuta S, Marshall WS. Lack of detectable oral bioavailability of plant microRNAs after feeding in mice. Nat Biotechnol 2013; 31: 965-7.
79. [79] Snow JW, Hale AE, Isaacs SK, Baggish AL, Chan SY. Ineffective delivery of diet-derived microRNAs to recipient animal organisms. RNA Biol 2013; 10: 1107-16.
80. [80] Witwer KW, McAlexander MA, Queen SE, Adams RJ. Real-time quantitative PCR and droplet digital PCR for plant miRNAs in mammalian blood provide little evidence for general uptake of dietary miRNAs: limited evidence for general uptake of dietary plant xenomiRs. RNA Biol 2013; 10: 1080-6.
81. [81] Zhang L, Hou D, Chen X, et al. Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res 2012; 22: 107-26.
82. [82] Chen X, Liang H, Zhang J, Zen K, Zhang CY. Horizontal transfer of microRNAs: molecular mechansism and clinical applications. Protein Cell 2012; 3: 28-37.
83. [83] Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.
84. [84] Hata T, Murakami K, Nakatani H, Yamamoto Y, Matsuda T, Aoki N. Isolation of bovine milk-derived microvesicles carrying mRNAs and microRNAs. Biochem Biophys Res Commun 2010; 396: 528-33.
85. [85] Chen X, Gao C, Li H, et al. Identification and characterization of microRNAs in raw milk during different periods of lactation, commercial fluid, and powdered milk products. Cell Res 2010; 20: 1128-37.
86. [86] Izumi H, Kosaka N, Shimizu T, Sekine K, Ochiya T, Takase M. Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions. J Dairy Sci 2012; 95: 4831-41.
87. [87] Reinhardt TA, Lippolis JD, Nonnecke BJ, Sacco RE. Bovine milk exosome proteome. J Proteomics 2012; 75: 1486-92.
88. [88] Izumi H, Kosaka N, Shimizu T, Sekine K, Ochiya T, Takase M. Purification of RNA from milk whey. Methods Mol Biol 2013; 1024:191-201.
89. [89] Sun Q, Chen X, Yu J, Zen K, Zhang CY, Li L. Immune modulatory function of abundant immune-related microRNAs in microvesicles from bovine colostrum. Protein Cell 2013; 4: 197-210.
90. [90] Baier SR, Nguyen C, Xie F, Wood JR, Zempleni J. MicroRNAs are absorbed in biologically meaningful amounts from nutritionally relevant doses of cow milk and affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney cell cultures, and mouse livers. J Nutr 2014; 144: 1495-1500.
91. [91] Kosaka N, Izumi H, Sekine K, Ochiya T. microRNA as a new immune-regulatory agent in breast milk. Silence 2010; 1: 7.
92. [92] Zhou Q, Li M, Wang X, et al. Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci 2012; 8: 118-23.
93. Howard KM, Kusuma RJ, Baier SR, et al. Loss of MiRNAs during processing and storage of cow’s (Bos taurus) milk. J Agric Food Chem 2015; [epub ahead of print].
94. [94] Jiang H, Wu W, Zhang M, et al. Aberrant upregulation of miR-21 in placental tissues of macrosomia. J Perinatol 2014; 34: 658-63.
95. [95] Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58.
96. [96] Han M, Liu M, Wang Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 incactivation by targeting PTEN. PLoS One 2012; 7: e39520.
97. [97] Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG: TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 2012; 7: e42316.
98. [98] Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrouths. Mol Biol Cell 2008; 19: 3272-82.
99. [99] Dariminpourain M, Wang S, Ittmann M, Kwabi-Addo B. Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer. Prostate Cancer Prostatic Dis 2011; 14: 279-85.
100. [100] Frey MR, Carraro G, Batra RK, Polk DB, Warburton D. Sprouty keeps bowel kinases regular in colon cancer, while miR-21 targets Sprouty. Cancer Biol Ther 2011; 11: 122-4.
101. [101] Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
102. [102] Lu Z, Liu M, Stribinskis V, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008; 27: 4373-9.
103. [103] Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 2008; 28: 8601-10.
104. [104] Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest 2012; 122: 1097-108.
105. [105] Dennis MD, Jefferson LS, Kimball SR. Role of p70S6K1-mediated phosphorylation of eIF4B and PDCD4 proteins in the regulation of protein synthesis. J Biol Chem 2012; 287: 42890-9.
106. [106] Kim YJ, Hwang SJ, Bae YC, Jung JS. MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells 2009; 27: 3093-102.
107. [107] Kim YJ, Hwang SH, Cho HH, Shin KK, Bae YC, Jung JS. MicroRNA 21 regulates the proliferation of human adipose tissuederived mesenchymal stem cells and high-fat diet-induced obesity alters microRNA 21 expression in white adipose tissues. J Cell Physiol 2012; 227: 183-93.
108. [108] Dey N, Das F, Mariappan MM, et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem 2011, 286: 25586-603.
109. [109] Zhong X, Chung AC, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56: 663-74.
110. [110] Lei BX, Liu ZH, Li ZJ, Li C, Deng YF. miR-21 induces cell proliferation and suppresses the chemosensitivity in glioblastoma cells via downregulation of FOXO1. Int J Clin Exp Med 2014, 7: 2060-6.
111. [111] Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008; 27: 2320-36.
112. [112] Kitamura T, Ido Kitamura Y. Role of FoxO proteins in pancreatic beta cells. Endocr J 2007; 54: 507-15.
113. [113] Kobayashi M, Kikuchi O, Sasaki T, et al. FoxO1 as a double-edged sword in the pancreas: analysis of pancreas-and β-cell-specific FoxO1 knockout mice. Am J Physiol Endocrinol Metab 2012; 302: E603-13.
114. [114] Martinez SC, Cras-Méneur C, Bernal-Mizrachi E, Permutt MA. Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet beta-cell. Diabetes 2006; 55: 1581-91.
115. [115] Guo S, Dunn SL, White MF. The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. Mol Endocrinol 2006; 20: 3389-99.
116. [116] Dansen TB. Forkhead Box O transcription factors: key players in redox signaling. Antioxid Redox Signal 2011; 14: 559-61.
117. [117] Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005; 2: 153-63.
118. [118] Anuradha R, Saraswati M, Kumar KG, Rani SH. Apoptosis of beta cells in diabetes mellitus. DNA Cell Biol 2014; 33: 743-8.
119. [119] Adibi SA. Influence of dietary deprivations on plasma concentration of free amino acids of man. J Appl Physiol 1968; 25: 52-7.
120. [120] Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med 1969; 281: 811-6.
121. [121] Belfiore F, Iannello S, Rabuazzo AM. Insulin resistance in obesity: a critical analysis at enzyme level. A review. Int J Obes 1979; 3: 301-23.
122. [122] Pennetti V, Galante A, Zonta-Sgaramella L, Jayakar SD. Relation between obesity, insulinemia, and serum amino acid concentrations in a sample of Italian adults. Clin Chem 1982; 28: 2219-24.
123. [123] Nair KS, Garrow JS, Ford C, Mahler RF, Halliday D. Effect of poor diabetic control and obesity on whole body protein metabolism in man. Diabetologia 1983; 25: 400-3.
124. [124] Forlani G, Vannini P, Marchesini G, Zoli M, Ciavarella A, Pisi E. Insulin-dependent metabolism of branched-chain amino acids in obesity. Metabolism 1984; 33: 147-50.
125. [125] Schauder P, Zavelberg D, Langer K, Herbertz L. Sex-specific differences in plasma branched-chain keto acid levels in obesity. Am J Clin Nutr 1987; 46: 58-60.
126. [126] Caballero B, Finer N, Wurtman RJ. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. Metabolism 1988; 37: 672-6.
127. [127] She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab 2007; 293: E1552-63.
128. [128] Newgard CB, An J, Bain JR, et al. A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabol 2009; 9: 311-26.
129. [129] Zeng M, Che Z, Liang Y, et al. GC-MS based plasma metabolic profiling of type 2 diabetes. Chromatographia 2009; 69: 941-8.
130. [130] Zeng YJ, Zeng FQ, Dai L, et al. Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus. Lupus 2010; 19: 1344-50.
131. [131] Tai ES, Tan ML, Stevens RD, et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 2010; 53: 757-67.
132. [132] Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 2010; 5: e13953.
133. [133] Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One 2010; 5: e15234.
134. [134] Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-53.
135. [135] Würtz P, Mäkinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012; 61: 1372-80.
136. [136] Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012; 15: 606-14.
137. [137] Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012; 125: 2222-31.
138. [138] McCormack SE, Shaham O, McCarthy MA, et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 2013; 8: 52-61.
139. [139] Lackey DE, Lynch CJ, Olson KC, et al. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab 2013; 304: E1175-87.
140. [140] Kim MJ, Yang HJ, Kim JH, et al. Obesity-related metabolomic analysis of human subjects in black soybean peptide intervention study by ultraperformance liquid chromatography and quadrupoletime-of-flight mass spectrometry. J Obes 2013; 2013: 874981.
141. [141] Morris C, O'Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, Brennan L. The relationship between BMI and metabolomic profiles: a focus on amino acids. Proc Nutr Soc 2012; 71: 634-8.
142. [142] Lu J, Xie G, Jia W, Jia W. Insulin resistance and the metabolism of branched-chain amino acids. Front Med 2013; 7:53-9.
143. [143] Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr 2006; 136: 207S-11S.
144. [144] Islam MM, Nautiyal M, Wynn RM, Mobley JA, Chuang DT, Hutson SM. Branched-chain amino acid metabolon: interaction of glutamate dehydrogenase with the mitochondrial branched-chain aminotransferase (BCATm). J Biol Chem 2010; 285: 265-76.
145. [145] AEvarsson A, Chuang JL, Wynn RM, Turley S, Chuang DT, Hol WG. Crystal structure of human branched-chain alpha-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure 2000; 8: 277-91.
146. [146] Mersey BD, Jin P, Danner DJ. Human microRNA (miR29b) expression controls the amount of branched chain alpha-ketoacid dehydrogenase complex in a cell. Hum Mol Genet 2005; 14: 3371-7.
147. [147] Davie JR, Wynn RM, Meng M, et al. Expression and characterization of branched-chain alpha-ketoacid dehydrogenase kinase from the rat. Is it a histidine-protein kinase? J Biol Chem 1995; 270: 19861-7.
148. [148] Chou PY, Fasman GD. Structural and functional role of leucine residues in proteins. J Mol Biol 1973; 74: 263-81.
149. [149] Hawgood S, Derrick M, Poulain F. Structure and properties of surfactant protein B. Biochim Biophys Acta 1998; 1408: 150-60.
150. [150] Glover JN, Harrison SC. Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 1995; 373: 257-61.
151. [151] Wiley AS. Dairy and milk consumption and child growth: Is BMI involved? An analysis of NHANES 1999-2004. Am J Hum Biol 2010; 22: 517-25.
152. [152] Berkey CS, Rocket HR, Willet WC, Colditz GA. Milk, dairy fat, dietary calcium, and weight gain. Arch Pediatr Adolesc Med 2005; 159: 543-50.
153. [153] Matthews VL, Wien M, Sabaté J. The risk of child and adolescent overweight is related to types of food consumed. Nutr J 2011; 10: 71.
154. [154] Arnberg K, Mølgaard C, Michaelsen KF, Jensen SM, Trolle E, Larnkjær A. Skim milk, whey, and casein increase body weight and whey and casein increase plasma C-peptide concentration in overweight adolescents. J Nutr 2012; 142: 2083-90.
155. [155] Barr SI, McCarron DA, Heaney RP, et al. Effects of increased consumption of fluid milk on energy and nutrient intake, body weight, and cardiovascular risk factors in healthy older adults. Am J Diet Assoc 2000; 100: 810-7.
156. [156] Seeger T, Fischer A, Muhly-Reinholz M, Zeiher AM, Dimmeler S. Long-term inhibition of miR-21 leads to reduction of obesity in db/db mice. Obesity (Silver Spring) 2014; 22: 2352-60.
157. [157] Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014; 10: 723-36.
158. [158] Tiffin N, Adie E, Turner F, et al. Computational disease gene identification: a concert of methods prioritizes type 2 diabetes and obesity candidate genes. Nucleic Acids Res 2006; 34: 3067-81.
159. [159] Zhu H, Shyh-Chang N, Segrè AV, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011; 147: 81-94.
160. [160] Viswanathan SR, Dalex GQ, Gregory RI. Selective blockade of microRNA processing by Lin-28. Science 2008; 320: 97-100.
161. [161] Pérez LM, Bernal A, San Martin N, Lorenzo M, Fernández-Veledo S, Gávez BG. Metabolic rescue of obese adipose-derived stem cells by Lin28/Let7 pathway. Diabetes 2013; 62: 2368-79.
162. [162] Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic diesease. Cardiovasc Res 2013; 100: 7-18.
163. [163] Yang WM, Jeong HJ, Park SY, Lee W. Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. FEBS Lett 2014; 588: 2170-6.
164. [164] Chakraborty C, Doss CG, Bandyopadhyay S, Agoramoorthy G. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes. Wiley Interdiscip Rev RNA 2014; 5: 697-712.
165. [165] Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13: 252-9.
166. [166] Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012; 441: 1-21
167. [167] Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR. Bidirectional modulation of insulin action by amino acids. J Clin Invest 1998; 101: 1519-9.
168. [168] Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acidinduced skeletal muscle insulin resistance in humans. Diabetes 2002; 51: 599-605.
169. [169] Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-6.
170. [170] Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431: 200-5.
171. [171] Tremblay F, Krebs M, Dombrowski L, et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005; 54: 2674-84.
172. [172] Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006; 3: 393-402.
173. [173] Tremblay F, Brulé S, Hee Um S, et al. Identification of Ser-1101 as a target of S6K1 in nutrient-and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2007; 104: 14056-61.
174. [174] Gulati P, Thomas G. Nutrient sensing in the mTOR/S6K1 signalling pathway. Biochem Soc Trans 2007; 35: 236-8.
175. [175] Lawlor DA, Smith GD, O'Callaghan M, et al. Epidemiologic evidence for the fetal overnutrition hypothesis: findings from the Mater-University Study of Pregnancy and its Outcomes. Am J Epidemiol 2007; 165: 418-24.
176. [176] Davey Smith G, Steer C, Leary S, Ness A. Is there an intrauterine influence on obesity? Evidence from parent child associations in the Avon Longitudinal Study of Parents and Children (ALSPAC). Arch Dis Child 2007, 92:876-880.
177. [177] Catalano PM, Farrell K, Thomas A, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr 2009; 90: 1303-13.
178. The American College of Obstetricians and Gynecologists. FAQ1. Nutrition during pregnancy. Sep 2013; http://www.acog.org/~/media/For%20Patients/faq001.Pdf?dmc=1&ts=20140823T1014147121.
179. [179] Olsen SF, Halldorsson TI, Willett WC, et al. Milk consumption during pregnancy is associated with increased infant size at birth: prospective cohort study. Am J Clin Nutr 2007; 86: 1104-10.
180. [180] Heppe DH, van Dam RM, Willemsen SP, et al. Maternal milk consumption, fetal growth, and the risks of neonatal complications: the Generation R Study. Am J Clin Nutr 2011; 94: 501-9.
181. [181] Lager S, Oowell TL. Regulation of nutrient transport across the placenta. J Pregnancy 2012; 2012: 179827.
182. [182] Larqué E, Riuz-Palacios M, Koletzko B. Placental regulation of fetal nutrient supply. Curr Opin Clin Nutr Metab Care 2013; 16: 292-7.
183. [183] Roos S, Jansson N, Palmberg I, Säljö K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted growth. J Physiol 2007; 582: 449-59.
184. [184] Jansson T, Aye IL, Goberdhan DC. The emerging role of mTORC1 signaling in placental nutrient-sensing. Placenta 2012; 33: e23-9.
185. [185] Roos S, Lagerlöf O, Wennergren M, Powell TL, Jansson T. Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR signaling. Am J Physiol Cell Physiol 2009; 297: C723-31.
186. [186] Jansson N, Rosario FJ, Gaccioli F, et al. Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies. J Clin Endocrinol Metab 2013; 98: 105-13.
187. Melnik BC, John SM, Schmitz G. Milk consumption during pregnancy increases birth weight, a risk factor for the development of diseases of civilization. J Transl Med 2015 [Epub ahead of print].
188. [188] Melnik BC. Formula feeding promtes adipogenic, diabetogenic, hypertonic and allergic mTORC1-programming. In: Preedy VR, Watson RR, Zibadi S (eds) Handbook of dietary and nutritinal aspects of bottle feeding. Human Health Handbooks no. 8, Wageningen Academic Publishers 2014, pp 545-568.
189. [189] Melnik BC. Excessive leucine-mTORC1-signalling of cow milkbased infant formula: the missing link to understand early childhood obesity. J Obes 2012; 2012: 197653.
190. [190] Escribano J, Luque V, Ferre N, et al. Effect of protein intake and weight gain velocity on body fat mass at 6 months of age: the EU Childhood Obesity Programme. Int J Obes 2012; 36: 548-53.
191. [191] Koletzko B, Beyer J, Brands B, et al. Early influences of nutrition on postnatal growth. Nestle Nutr Inst Workshop Ser 2013; 71, 11-27.
192. [192] Dunger DB, Salgin B, Ong KK. Session 7: Early nutrition and later health. Early developmental pathways of obesity and diabetes risk. Proc Nutr Soc 2007; 66: 451-7.
193. [193] Wiley AS. Milk intake and total dairy consumption: associations with early menarche in NHANES 1999-2004. PLoS One 2011; 6: e14685.
194. [194] Janghorbani M, Mansourian M, Hosseini E. Systematic review and meta-analysis of age at menarche and risk of type 2 diabetes. Acta Diabetol 2014; 51: 519-28.
195. [195] Bartolome A, Guillén C. Role pf the mammalian target of rapamycin (mTOR) complexes in pancreatic β-cell mass regulation. Vitam Horm 2014; 95: 425-69.
196. [196] Back SH; Kang SW, Han J, Chung HAT. Endoplasmic reticulum stress in the β-cell cell pathogenesis of type 2 diabetes. Exp Diabetes Res 2012; 2012: 618396.
197. [197] Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem. 2012; 81: 767-93
198. [198] Cnop M, Ladriere L, Igoillo-Esteve M, Moura RF, Cunha DA. Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction. Diabetes Obes Metab 2010; 12: 76-82.
199. [199] Meier JJ, Breuer TG, Bonadonna RC, et al. Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia 2012; 55: 1346-54.
200. [200] Bachar E, Ariav Y, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic β-cells via activation of mTORC1. PLoS One 2009; 4: e4954.
201. [201] Reiling JH, Sabatini DM. Increased mTORC1 singaling UPRegulates stress. Mol Cell 2008; 29: 533-5.
202. [202] Kato H, Nakajima S, Saito Y, Takahashi S, Katoh R, Kitamura M. mTORC1 serves ER stress-triggered apoptosis via selective activation oft he IRE-JNK pathway. Cell Death Differ 2012; 19: 310-20.
203. [203] Ozcan U, Ozcan L, Yilmaz E, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008; 29: 541-51.
204. [204] Krokowski D, Han J, Saikia M, et al. A self-defeating anabolic program leads to β-cell apoptosis in endoplasmic reticulum stressinduced diabetes via regulation of amino acid flux. J Biol Chem 2013; 288: 17202-13.
205. [205] Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol 2012; 22: 274-82.
206. [206] Guan BJ, Krokowski D, Majumder M, et al. Translational control during endoplasmic reticulum stress beyond phosphorylation of the translation initiation factor eIF2β. J Biol Chem 2014; 289: 12593-611.
207. [207] Han J, Back SH, Hur J, et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 2013; 15: 481-90.
208. [208] Dunlop EA, Tee AR. mTOR and autophagy: A dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol 2014; 36C: 121-129.
209. [209] Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13: 132-41.
210. [210] Bachar-Wikstrom E, Wikstrom JD, Kaiser N, Cerasi E, Leibowitz G. Improvement of ER stress-induced diabetes by stimulating autophagy. Autophagy 2013; 9: 626-8.
211. [211] Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy 2010; 6: 239-47.
212. [212] Shigeyama Y, Kobayashi T, Kido Y, et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 2008; 28: 2971-9.
213. [213] Tang X, Tang G, Ozcan S. Role of microRNAs in diabetes. Biochim Biophys Acta 2008; 1779: 697-701.
214. [214] Ozcan S. Minireview: MicroRNA function in pancreatic β cells. Mol Endocrinol 2014; 28: 1922-1933.
215. [215] Plaisance V, Waeber G, Regazzi R, Abderrahmani A. Role of microRNAs in islet beta-cell compensation and failure during diabetes. J Diabetes Res 2014; 2014: 618652.
216. [216] Roggli E, Britan A, Gattesco S, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 2010; 59: 978-86.
217. [217] Novotny GW, Lundh M, Backe MB, et al. Transcriptional and translational regulation of cytokine signaling in inflammatory β-cell dysfunction and apoptosis. Arch Biochem Biophys 2012; 528: 171-84.
218. [218] Dai C, Brissova M, Reinert RB, et al. Pancreatic islet vasculature adapts to insulin resistance through dilation and not angiogenesis. Diabetes 2013; 62: 4144-53.
219. [219] Eberhard D, Kragl M, Lammert E. 'Giving and taking': endothelial and beta-cells in the islets of Langerhans. Trends Endocrinol Metab 2010; 21: 457-63.
220. [220] Zanone MM, Favaro E, Camussi G. From endothelial to beta cells: insights into pancreatic islet microendothelium. Curr Diabetes Rev 2008; 4: 1-9.
221. [221] Salama A, Fichou N, Allard M, et al. MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity. PLoS One 2014; 9: e106153.
222. [222] Figliolini F, Cantaluppi V, De Lena M, et al. Isolation, characterization and potential role in beta cell-endothelium cross-talk of extracellular vesicles released from human pancreatic islets. PLoS One 2014; 9: e102521.
223. [223] Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac expression oft he diabetic marker microRNA miR-29. PloS One 2014; 9: e103284.
224. [224] Nielsen LB, Wang C, Sørensen K, et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual betacell function and glycaemic control during disease progression. Exp Diabetes Res 2012; 2012: 896362.
225. [225] Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-44.
226. [226] Mott JL, Kobayashi S, Bronk SF, Gores GJ. Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-40.
227. [227] Roggli E, Gattesco S, Caille D, et al. Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes 2012; 61: 1742-5.
228. [228] He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly upregulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21: 2785-94.
229. [229] Peng H, Zhong M, Zhao W, et al. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS One 2013; 8: e82607.
230. [230] Mills JR, Hippo Y, Robert F, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 2008; 105: 10853-8.
231. [231] Pereira MA, Jacobs DR Jr, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study JAMA 2002; 287: 2081-9.
232. [232] Elwood PC, Pickering JE, Givens DI, Gallacher JE. The consumption of milk and dairy foods and the incididence of vascular disease and diabetes: an overview of the evidence. Lipids 2010; 45: 925-39.
233. [233] Fumeron F, Lamri A, Abi Khalil C, et al. Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome: results from a French prospective study, Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2011; 34: 813-7.
234. [234] Tong X, Dong JY, Wu ZW, Li W, Qin LQ. Dairy consumption and risk of type 2 diabetes mellitus: a meta-analysis of cohort studies. Eur J Clin Nutr 2011; 65: 1027-31.
235. [235] Hirahatake KM, Slavin JL, Maki KC, Adams SH. Associations between dairy foods, diabetes, and metabolic health: Potential mechanisms and future directions. Metabolism 2014; 63: 618-27.
236. [236] Rice BH, Quann EE, Miller GD. Meeting and exceeding dairy recommendations: effects of dairy consumption on nutrient intakes and risk of chronic disease. Nutr Rev 2013; 71: 209-23.
237. [237] Liu S, Choi HK, Ford E, et al. A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care 2006; 29: 1579-84.
238. [238] Elwood PC, Pickering JE, Fehily AM. Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. J Epidemiol Community Health 2007; 61: 695-8.
239. [239] Villegas R, Gao YT, Dai Q, et al. Dietary calcium and magnesium intakes and the risk of type 2 diabetes: the Shanghai Women's Health Study. Am J Clin Nutr 2009; 89: 1059-67.
240. [240] Kirii K, Mizoue T, Iso H, et al. Calcium, vitamin D and dairy intake in relation to type 2 diabetes risk in a Japanese cohort. Diabetologia 2009; 52: 2542-50.
241. [241] Song Y, Chavarro JE, Cao Y, et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr 2013; 143: 189-96.
242. [242] Sluijs I, Forouhi NG, Beulens JW, et al. The amount and type of dairy product intake and incident type 2 diabetes: results from the EPIC-InterAct Study. Am J Clin Nutr 2012; 96: 382-90.
243. [243] Gobierno de España, Ministerio de Agricultura, Alimentación y Medio Ambiente. El Consumo Alimentario en España. 2011.
244. [244] Liljeberg Elmståhl H, Björck I. Milk as a supplement to mixed meals may elevate postprandial insulinaemia. Eur J Clin Nutr 2001; 55: 994-9.
245. [245] Dunne J, Evershed RP, Salque M, et al. First dairying in green Saharan Africa in the fifth millennium BC. Nature 2012; 486: 390-4.
246. [246] Curry A. Archaeology: The milk revolution. Nature 2013; 500: 20-2.
247. [247] Beja-Pereira A, Luikart G, England PR, et al. Gene-culture coevolution between cattle milk protein genes and human lactase genes. Nat Genet 2003; 35: 311-3.
248. [248] Panesar PS, Kumari S, Panesar R. Potential applications of immobilized β-galactosidase in food processing industries. Enzyme Res 2010; 2010: 473137.
249. [249] Yu R, Woo J, Chan R, et al. Relationship between dietary intake and the development of type 2 diabetes in a Chinese population: the Hong Kong Dietary Survey. Public Health Nutr 2011; 14: 1133-41.
250. [250] van Nielen M, Feskens EJ, Mensink M, et al. Dietary protein intake and incidence of type 2 diabetes in Europe: the EPIC-InterAct Case-Cohort Study. Diabetes Care 2014; 37: 1854-62.
251. [251] Michaëlsson K, Wolk A, Langenskiöld S, et al. Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ 2014; 349: g6015.
252. [252] Upadhyaya S, Kadamkode V, Mahammed R, Doraiswami C, Banerjee G. Adiponectin and IL-6: Mediators of inflammation in progression of healthy to type 2 diabetes in Indian population. Adipocyte 2014; 3: 39-45.
253. [253] Oh YS, Lee YJ, Park EY, Jun HS. Interleukin-6 treatment induces beta-cell apoptosis via STAT-3-mediated nitric oxide production. Diabetes Metab Res Rev 2011; 27: 813-9.
254. [254] Russell MA, Cooper AC, Dhayal S, Morgan NG. Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells. Islets 2013; 5: 95-105.
255. [255] Yang CH, Yue J, Fan M, Pfeffer LM. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010; 70: 8108-16.
256. [256] Ou H, Li Y, Kang M. Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene. PLoS One 2014; 9: e109929.
257. [257] Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53.
258. [258] Song S, Abdelmohsen K, Zhang Y, Becker KG, Gorospe M, Bernier M. Impact of pyrrolidine dithiocarbamate and interleukin-6 on mammalian target of rapamycin complex 1 regulation and global protein translation. J Pharmacol Exp Ther 2011; 339: 905-13.
259. [259] McCay CM, Crowell MF. Prolonging the life span. Scientific Monthly 1934; 39: 405-14.
260. [260] Moss M. Does milk cause coronary heart diesease? J Nutr Environment Med 2002; 12: 207-16.
261. [261] Segall JJ. Hypothesis: Is lactose a dietary risk factor for ischaemic heart disease? Int J Epidemiol 2008; 37: 1204-8.
262. [262] Ji J, Sundquist J, Sundquist K. Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a populationbased study in Sweden. Br J Cancer 2015; 112: 149-152.
263. [263] Melnik BC, John SM, Carrera-Bastos P, Cordain L. The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond) 2012; 9: 74.
264. [264] Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 2014; 16: 378-86.
265. [265] Melnik BC, Schmitz G. Metformin: an inhibitor of mTORC1 signaling. J Endocrinol Diabetes Obes 2014; 2: 1029.
266. [266] Malek M, Aghili R, Emami Z, Khamseh ME. Risk of cancer in diabetes: the effect of metformin. Endocrinology 2013; 2013: 636927.
267. [267] Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes life longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16: 1165-73.
268. [268] Blagosklonny MV. Revisiting the antagonistic peiotropy theory of aging. TOR-driven program and quasi-program. Cell Cycle 2010; 9: 3151-6.
269. [269] Kapahi P, Chen D, Rogers AN, et al. With TOR less is more: a key role for the conserved nutrient sensing TOR pathway in aging. Cell Metab 2010; 11: 453-65.
270. [270] Weaver CM. How sound is the science behind the dietary recommendations for dairy? Am J Clin Nutr 2014; 99: 1217S-22S.
271. [271] McGregor RA, Poppitt SD. Milk protein for improved metabolic health: a review of the evidence. Nutr Metab (Lond) 2013; 10: 46.
272. Tunick MH, Van Hekken DL. Dairy products and health: recent insights. J Agric Food Chem 2014; Nov 19 [Epub ahead of print].
273. [273] Chen M, Sun Q, Giovannucci E, et al. Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated metaanalysis. BMC Med 2014; 12: 215.
274. [274] Wise J. Eating a yoghurt a day is linked to lower risk of type 2 diabetes. BMJ 2014; 349: g7081.